Vir Biotechnology (VIR) director awarded 8,000 RSUs and 16,000-share stock option
Rhea-AI Filing Summary
Vir Biotechnology director Ramy Farid reported routine equity compensation awards. He received 8,000 shares of Common Stock as restricted stock units under the company’s equity incentive plan, bringing his direct holdings to 32,000 shares after the grant.
He was also granted a stock option for 16,000 shares of Common Stock at an exercise price of $9.10 per share. Both the RSUs and the option are scheduled to vest in full on May 27, 2027, and the option expires on May 26, 2036. These are compensation-related acquisitions, not open-market purchases.
Positive
- None.
Negative
- None.
Insights
Routine director equity awards with time-based vesting.
Vir Biotechnology granted director Ramy Farid 8,000 RSUs and an option for 16,000 shares at $9.10, all vesting in full on May 27, 2027. These are standard board compensation tools, not market transactions.
The filing shows Farid now directly holds 32,000 common shares plus this new option position. Because these awards are part of an equity incentive plan and not open-market buying or selling, they carry limited signaling value for the company’s short-term outlook.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 16,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 8,000 | $0.00 | $0.00 |
Footnotes (3)
- F1. Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
- F2. The RSUs will vest in full on May 27, 2027.
- F3. The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.
Key Figures
Key Terms
restricted stock units (RSUs) financial
Equity Incentive Plan financial
stock option financial
Common Stock financial
AI-generated analysis. How Rhea-AI works. Not financial advice.